Find company announcements below, or check out the latest news in the right side menu.
1. October 2007
Effective from October 1, 2007 Novozymes A/S has completed the acquisition of the enzyme activities of Biocon Limited, Bangalore, India. In reference to Stock exchange announcement no.
20. September 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
5. September 2007
28. August 2007
Novozymes announces that the Board has appointed two new Executive Vice Presidents for Novozymes’ Executive Management, namely Thomas Nagy and Thomas Videbæk.
13. August 2007
9. August 2007
Novozymes’ results for the first half of 2007 are fully in line with the outlook. Sales rose by 14%, while operating profit rose by 20% including one-off items and by 9% based on ordinary activities.
18. July 2007
Novozymes A/S (“Novozymes”) has today signed a definitive agreement under which it will acquire the enzyme activities of Biocon Limited (”Biocon”), Bangalore, India. Novozymes does not currently hold any stake in Biocon.
1. June 2007
Pursuant to the implementation of the EU Transparency Obligations Directive into Danish law, hereunder Executive Order no. 226 of 15 March 2007 on Obligations of Issuers, the following information about the total number of voting rights and the total share capital of Novozymes A/S is hereby given.
25. April 2007
Growth in the first quarter of 2007 was significantly higher than expected. Sales grewby 18%, operating profit by 15%, and net profit for the period by 30%, as a result of which Novozymes is adjusting its outlook for 2007 upwards.
17. April 2007
Novozymes A/S will receive a total settlement of USD 15.3 million in connection with the termination of the US patent infringement suit against Danisco A/S.
3. April 2007
The new business area is named Biopharmaceutical Ingredients, and will comprise the activities related to Novozymes Delta, Novozymes GroPep, Novozymes Biopharma and also the research project within recombinant human serum albumin (rHSA).
9. March 2007
The Annual Meeting of Shareholders in Novozymes A/S took place yesterday, with the report on the company’s activities in the last financial year being adopted.
2. March 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B
28. February 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transaction under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
19. February 2007
Novozymes A/S (Bagsvaerd, Denmark) awarded double damages, attorneys' fees and costs. Danisco found to have wilfully infringed Novozymes' patent.
14. February 2007
12. February 2007
9. February 2007
5. February 2007
1. February 2007
31. January 2007
25. January 2007
2006 was a very satisfactory year for Novozymes. Growth of 11% in earnings, 8% in sales and free cash flow of DKK 1,058 million were fully in line with the outlook. Growth is expected to continue in 2007.
12. December 2006
Novozymes A/S has completed the acquisition of Australian company GroPep Ltd with effect from December 12, 2006.
10. December 2013
| Copyright © 2013 Novozymes. All Rights Reserved.